March 4, 2024
Louise-Brett-Terrapay-independent-Director

Sight Sciences appoints Catherine Mazzacco to its Board of Directors

Catherine Mazzacco, Sight Sciences, board of directors
Catherine Mazzacco, Sight Sciences, board of directors

Sight Sciences, Inc. (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, recently announced that Catherine Mazzacco was elected to the Company’s board of directors at its Annual Meeting of Stockholders held on June 8, 2023. Ms. Mazzacco will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders.  

“We are very excited to have Catherine on our board of directors. We have added an industry veteran with a track record of success in commercial and operational leadership at large healthcare businesses with global scale. Catherine’s experience at Abbott, as General Manager of its Immunology division that launched Humira, one of the most successful healthcare products on record, and leading the global commercial operations for Abbott’s AMO ophthalmic division, is particularly relevant to the continued growth and global expansion of Sight Sciences. Catherine’s strategic insight will further elevate our company as we scale our business,” said Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences.     

Sight Sciences

Ms. Mazzacco added, “I am thrilled to join the board of Sight Sciences at this exciting time as the glaucoma and dry eye categories are undergoing significant transformation and the company advances its compelling product pipeline. Sight Sciences is very well positioned to enhance the lives of patients around the world by elevating the standards of care in eyecare while delivering significant value to the ophthalmic community and stakeholders. I look forward to collaborating with this top-tier team and board to help the company achieve its growth and profitability objectives.”

Ms. Mazzacco was formerly Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company, and a member of its board of directors from August 2019 to November 2021. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, of the Life Sciences Division at GE HealthCare, a leading global medical technology, pharmaceutical, diagnostics and life sciences company, from February 2018 to May 2019. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories, a major multinational publicly traded healthcare company where she held several global senior operational and strategic leadership roles, including Vice President, Global Commercial Operations, of the Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served as a member of the board of directors of Krystal Biotech, Inc. since March 2023.  Ms. Mazzacco is also a Member of the Supervisory Board of Servier, a privately owned global pharmaceutical company. Ms. Mazzacco holds a Bachelor of Science in Engineering, Option Biotechnology from the University of Compiègne in France.

Source

(Visited 11 times, 1 visits today)

Share:

Facebook
Twitter
WhatsApp
LinkedIn

Comments are closed.

Social Media

Most Popular

LRMF missile
Aerojet Rocketdyne joins Lockheed Martin to develop LRMF missile
Maria Jackson
BOURNEWOOD HEALTH SYSTEMS onboards Maria Jackson as CEO
Tahini located in the vibrant One Central.
GRIT Hospitality launches Tahini in Dubai
3D-Systems-EXT-1070-Titan-Pellet-printer
3D Systems and SWANY partnership to promote large-format pellet extrusion 3D printing

Related Posts